An Exciting New Drug Is in Clinical Trials for Aurinia Pharmaceuticals
Richard Glickman was the CEO of Aspreva Pharmaceuticals, which put out CellCept, a drug that treats patient with lupus who develop kidney disease. Glickman has moved on to Aurinia Pharmaceuticals (NASDAQ: AUPH), and now is working on another drug, Voclosporin, for the same indication.
In this Industry Focus: Healthcare clip, Motley Fool analyst Kristine Harjes and contributor Todd Campbell explain what both drugs do, how far along in the FDA gauntlet Voclosporin is today, and why investors should be so excited to see whether or not it gets approved.
A full transcript follows the video.
Source: Fool.com
Aurinia Pharmaceuticals Inc. Aktie
5,18 €
1,65 %
Wenige Einschätzungen bei Aurinia Pharmaceuticals Inc. lassen noch kein klares Bild zu.
Dadurch ergibt sich bei einem Kursziel von 8 € ein stark positives Potenzial von 54.5% im Vergleich zum aktuellen Kurs von 5.18 € bei Aurinia Pharmaceuticals Inc..
